TearClear Stock
TearClear is a pharmaceutical company that specializes in providing a disruptive eye health technology.
Sign up today and learn more about TearClear Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About TearClear Stock
TearClear is a pharmaceutical company that specializes in providing a class platform of drugs that enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. Founded in 2015, TearClear is headquartered in California, United States.
Investors
Bluestem Capital
Funding History
| May 2017 | $4.5M |
|---|---|
| April 2019 | $5.0M |
| January 2020 | $2.8M |
| August 2020 | $22.0M |
| April 2022 | $5.9M |
| July 2023 | $11.8M |
Management
Board of Director
Rick A. Heinick
Chief Scientific Officer and Co-Founder
Anuj Chauhan
Chief Executive Officer
Robert Dempsey
Co-Founder
Ken Banta
Founder
Rick A. Heinick
Board Member
Stuart Raetzman
Board Director
Bob Bailey
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
